Chinese e-commerce giant Alibaba has agreed to pay $600 million to settle allegations by the US Department of Justice that it failed to stop the sale of illegal drugs, restricted chemicals, and pharmaceutical counterfeiting equipment on its online platforms.
Under the agreement, Alibaba and its US-based payment processor, AUS Merchant Services, accepted responsibility for the actions of certain employees and pledged to strengthen their compliance and monitoring systems.
According to US authorities, Alibaba admitted that between 2016 and 2024, it failed to prevent about 80,000 sales of illegal drug-related products destined for the United States. The transactions were valued at more than $200 million.
Investigators said they carried out more than 40 undercover purchases of illegal pharmaceuticals and pill-making equipment during the probe. The Justice Department also revealed that some Alibaba employees had previously raised concerns about the sale of prohibited products and weaknesses in the company's compliance measures.
Alibaba said the settlement reflects its full cooperation with US regulators and reaffirmed its commitment to maintaining strict controls against the sale of illegal products.
The US government also said the payment processor failed to maintain an effective anti-money laundering programme, allowing some merchants to use its services to facilitate the sale and importation of banned products.
Alibaba operates some of the world's largest online marketplaces, including Alibaba.com and AliExpress.
.jpeg)
.jpeg "Sunayen kofofin aljanna guda takwas 8")
0 Comment about the Post: